Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Randomized, Multicenter, Phase 3 Trial

Next Previous
Trial Profile

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Randomized, Multicenter, Phase 3 Trial

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Cisplatin; Gemcitabine; Ropidoxuridine
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTINUUM

Most Recent Events

  • 06 Jun 2023 Primary endpoint (Failure-free survival (FFS)) has been met according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 06 Jun 2023 Results assessing safety and efficacy of sintilimab plus induction chemotherapy and concurrent chemoradiotherapy in locoregionally-advanced nasopharyngeal carcinoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 16 May 2023 According to an Innovent Biologics media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top